Latest UCB Stories
ATLANTA, June 9, 2011 /PRNewswire/ -- UCB, Inc. today announced an agreement with the U.S. Department of Justice (DOJ) to resolve a previously disclosed government investigation into the marketing and promotion of KeppraÂ®, an anti-epileptic prescription medicine.
BRUSSELS, June 9, 2011 /PRNewswire/ -- A post hoc analysis from the RECOVER study (Randomized Evaluation of the 24-hour Coverage: Efficacy of Rotigotine Transdermal System) suggested that patients with Parkinson's disease who used NeuproÂ® (rotigotine transdermal system) may experience improvements in key markers of mood/cognition, such as taking interest in surroundings and getting pleasure out of life.
BALTIMORE, May 31, 2011 /PRNewswire/ -- UCB announced findings of the first cost-effectiveness analysis of VimpatÂ® (lacosamide) as add-on therapy for adults with uncontrolled partial-onset seizures.
BRUSSELS, May 10, 2011 /PRNewswire/ -- UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology.
--Symposium Brings Together Industry, Investors, Scientific and Government Representatives to Advance Development of Drugs for Epilepsy-- MIDDLEBURG, Va., April 26, 2011 /PRNewswire-USNewswire/ -- The Epilepsy Therapy Project (ETP) today announced that a record number of emerging companies, industry executives, investors, scientific and government representatives will gather at the Antiepileptic Drug and Device Trials (AEDD) XI Conference to facilitate professional collaboration, funding and...
THOUSAND OAKS, Calif.
BRUSSELS, April 14, 2011 /PRNewswire/ -- New 5-year data from the longest prospective open-label Restless Legs Syndrome (RLS) study to date, show that NeuproÂ® (rotigotine) demonstrated continued symptomatic clinical benefit with a low risk of augmentation.
BRUSSELS, April 13, 2011 /PRNewswire/ -- New rotigotine data shown in four poster presentations at the 63rd Annual Meeting of the American Academy of Neurology (AAN) in Hawaii, U.S., highlighted the importance in Parkinson's disease (PD) of addressing both motor- and non-motor symptoms, such as sleep.
BRUSSELS and INCLINE VILLAGE, Nev., Feb. 8, 2011 /PRNewswire/ -- UCB SA (Euronext Brussels: UCB), on behalf of its affiliate UCB Pharma S.A. (UCB), and PDL BioPharma, Inc.
- A hairdresser.